Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays

por Adamkewicz, Joanne I., Kiialainen, Anna, Paz‐Priel, Ido
Publicado 2019

Loss of IKKβ but Not NF-κB p65 Skews Differentiation towards Myeloid over Erythroid Commitment and Increases Myeloid Progenitor Self-Renewal and Functional Long-Term Hematopoietic...

por Zhang, Jing, Li, Li, Baldwin, Albert S., Friedman, Alan D., Paz-Priel, Ido
Publicado 2015

CCAAT/Enhancer Binding Protein β Controls Androgen Deprivation-Induced Senescence in Prostate Cancer Cells

por Barakat, David J., Zhang, Jing, Barberi, Theresa, Denmeade, Samuel R., Friedman, Alan D., Paz-Priel, Ido
Publicado 2015

Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab

por Valls, Raquel, Wagg, Jonathan, Paz-Priel, Ido, Man, Gabriel, Artigas, Laura, Jaccard, Georges, Coma, Mireia, Schmitt, Christophe
Publicado 2023

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies

por Parnes, Aric, Mahlangu, Johnny N., Pipe, Steven W., Paz‐Priel, Ido, Lehle, Michaela, Trask, Peter C., Jiménez‐Yuste, Víctor
Publicado 2021

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study

por Kiialainen, Anna, Niggli, Markus, Kempton, Christine L., Castaman, Giancarlo, Chang, Tiffany, Paz‐Priel, Ido, Adamkewicz, Joanne I., Levy, Gallia G.
Publicado 2022

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis...

por Kempton, Christine, Trask, Peter, Parnes, Aric, Niggli, Markus, Campinha‐Bacote, Avrita, U. Callaghan, Michael, O'Connell, Niamh, Paz‐Priel, Ido, Mahlangu, Johnny N.
Publicado 2021

Low immunogenicity of emicizumab in persons with haemophilia A

por Schmitt, Christophe, Emrich, Thomas, Chebon, Sammy, Fernandez, Elena, Petry, Claire, Yoneyama, Koichiro, Kiialainen, Anna, Howard, Monet, Niggli, Markus, Paz‐Priel, Ido, Chang, Tiffany
Publicado 2021

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

por Skinner, Mark W., Négrier, Claude, Paz‐Priel, Ido, Chebon, Sammy, Jiménez‐Yuste, Victor, Callaghan, Michael U., Lehle, Michaela, Niggli, Markus, Mahlangu, Johnny, Shapiro, Amy, Shima, Midori, Campinha‐Bacote, Avrita, Levy, Gallia G., Oldenburg, Johannes, von Mackensen, Sylvia, Pipe, Steven W.
Publicado 2021

A Novel Chordoma Xenograft Allows In Vivo Drug Testing and Reveals the Importance of NF-κB Signaling in Chordoma Biology

por Trucco, Matteo M., Awad, Ola, Wilky, Breelyn A., Goldstein, Seth D., Huang, Ruili, Walker, Robert L., Shah, Preeti, Katuri, Varalakshmi, Gul, Naheed, Zhu, Yuelin J., McCarthy, Edward F., Paz-Priel, Ido, Meltzer, Paul S., Austin, Christopher P., Xia, Menghang, Loeb, David M.
Publicado 2013

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies

por Kruse-Jarres, Rebecca, Peyvandi, Flora, Oldenburg, Johannes, Chang, Tiffany, Chebon, Sammy, Doral, Michelle Y., Croteau, Stacy E., Lambert, Thierry, Kempton, Christine L., Pipe, Steven W., Ko, Richard H., Trzaskoma, Benjamin, Dhalluin, Christophe, Bienz, Nives Selak, Niggli, Markus, Lehle, Michaela, Paz-Priel, Ido, Young, Guy, Jiménez-Yuste, Víctor
Publicado 2022